PE-22-28 vs KPV
Side-by-side comparison of key properties, dosing, and research.
- Summary
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
- Half-Life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
- Admin Route
- SubQ, Intranasal
- Oral, SubQ, Topical
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 500 mcg – 1 mg
- Frequency
- Once daily
- Once to twice daily
- Key Benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Reduces intestinal inflammation (IBD, Crohn's, colitis)
- Promotes gut mucosal healing and barrier integrity
- Accelerates wound healing topically
- Suppresses systemic inflammatory cytokines
- Antimicrobial properties against pathogens
- Reduces neuroinflammation when administered systemically
- May improve symptoms of inflammatory skin conditions
- Side Effects
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Generally very well tolerated
- Mild injection site reactions (SC)
- Rare: transient flushing
- Stacks With
- —
- —